Rudy Li
Stock Analyst at Wolfe Research
(5.00)
# 18
Out of 5,182 analysts
40
Total ratings
80.56%
Success rate
113.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Peer Perform | n/a | $39.60 | - | 6 | Mar 31, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $34.99 | +28.61% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $217.38 | +5.81% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $56.44 | +6.31% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $32.89 | +21.62% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $27.66 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $19.62 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $330.02 | +51.51% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $152.25 | +5.09% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $22.05 | +13.38% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $22.40 | +47.32% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $85.50 | -6.43% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $11.63 | +157.95% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $24.26 | -38.17% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.86 | +4,572.90% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $10.73 | +67.75% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $39.60
Upside: -
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $34.99
Upside: +28.61%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $217.38
Upside: +5.81%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $56.44
Upside: +6.31%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $32.89
Upside: +21.62%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $27.66
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $19.62
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $330.02
Upside: +51.51%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $152.25
Upside: +5.09%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $22.05
Upside: +13.38%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $22.40
Upside: +47.32%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $85.50
Upside: -6.43%
Sep 29, 2025
Initiates: Buy
Price Target: $30
Current: $11.63
Upside: +157.95%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $24.26
Upside: -38.17%
Sep 29, 2025
Initiates: Buy
Price Target: $40
Current: $0.86
Upside: +4,572.90%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $10.73
Upside: +67.75%